Related Experiment Video

Updated: May 12, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Current role of short-term intensive insulin strategies in newly diagnosed type 2 diabetes

Wen Xu1, Jianping Weng

  • 1Department of Endocrinology, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Journal of Diabetes
|April 5, 2013
PubMed

Insights

Early intensive insulin therapy for type 2 diabetes mellitus (T2DM) can improve beta-cell function and glycemic control, potentially delaying disease progression better than traditional approaches.

Area of Science:

  • Endocrinology
  • Metabolic Diseases
  • Pharmacology

Background:

  • Type 2 diabetes mellitus (T2DM) is a progressive condition marked by increasing insulin resistance and declining beta-cell function.
  • Traditional T2DM management often delays insulin use, potentially missing opportunities for early intervention.
  • Glycemic control in T2DM becomes increasingly difficult as beta-cell function deteriorates.

Purpose of the Study:

  • To review the clinical benefits and mechanisms of early short-term intensive insulin therapy (SIIT) in newly diagnosed T2DM.
  • To discuss the potential of SIIT to improve beta-cell function and long-term glycemic outcomes.
  • To provide a perspective on the optimal use of SIIT in T2DM management.

Main Methods:

  • Review of current literature on early intensive insulin therapy in T2DM.
  • Analysis of studies investigating the impact of SIIT on beta-cell function, glycemic control, and related metabolic parameters.
  • Discussion of potential biological mechanisms underlying the effects of SIIT.

Main Results:

  • Early SIIT in T2DM can enhance beta-cell function and improve insulin sensitivity.
  • Patients receiving early SIIT demonstrate better glucose control and longer glycemic remission compared to oral antidiabetic agents.
  • Improvements in lipid profiles are also associated with early intensive insulin treatment.

Conclusions:

  • Administering SIIT to patients with newly diagnosed T2DM may delay disease progression.
  • Early insulin initiation should be considered as a treatment option for newly diagnosed T2DM.
  • Further research is needed to define optimal timing and pragmatic approaches for early SIIT in T2DM.
Keywords:
glycemic remissioninsulin therapytype 2 diabetesβ-cell function血糖缓解，胰岛素治疗，2型糖尿病，β细胞功能

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Type II Diabetes I: Introduction01:26

Type II Diabetes I: Introduction

Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...